The Enhanced Games, billed as the 'steroid Olympics,' were a dud. Not only did athletes fail to impress with world-beating feats, but their promoters also reported a $62 million loss from hosting these so-called games. The company behind this spectacle, Enhanced Group, was founded in 2023 and had enjoyed a successful IPO earlier that year, valued at $1.2 billion. Yet, the bulk of this valuation came from sponsorships tied to the games rather than their core telehealth business.

Despite the financial setback, the peptide industry is booming. A recent decision by the FDA to reclassify certain substances has given it a boost. This move is part of a broader trend in Silicon Valley where companies like Superpower and Noho Labs are capitalizing on biohacking and trendy health supplements. However, as this sector grows, state governments struggle to keep up with regulatory schemes.

Enhanced Group may already be pivoting, launching a new online series called Enhanced Breakers that could offer a cheaper alternative to the grandiose games while still maintaining engagement with sponsors and audiences. Yet, questions remain over whether these biotech advancements are just another form of tech spectacle or if they truly represent meaningful progress.

The industry's momentum is undeniable, but so too are the ethical concerns it raises. Enhanced Group’s woes highlight the risk of chasing quick profits through controversial means rather than sustainable business practices.